EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

FAP-CD40 and PD1-IL2v combination therapy reprograms immunologically cold tumors through de novo intratumoral T cell-dendritic cell clusters

Thuy Trinh Nguyen, Harold Gómez, Mechthild Lutge, Emilio Yángüez, Tamara Hüsser, Sina Nassiri, Christine Trumpfheller, Sara Colombetti, Laura Codarri Deak, Pablo Umaña, Sònia Tugues, Ines Grazina de Matos und 1 weitere

Journal for ImmunoTherapy of Cancer · 2026

DOI: 10.1136/jitc-2025-014620 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Thuy Trinh Nguyen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland. Hauptthemen laut MEDLINE: Dendritic Cells, CD40 Antigens, Programmed Cell Death 1 Receptor, Membrane Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: F. Hoffmann-La Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pancreatic ductal adenocarcinoma (PDAC) remains a major challenge for immunotherapy due to its immunologically cold tumor nature, characterized by poor T cell infiltration and a highly suppressive tumor microenvironment. Here, we propose a novel strategy, combining fibroblast activation protein (FAP)-CD40 to activate dendritic cells (DCs) in the tumor microenvironment and programmed cell death protein-1 (PD1)-interleukin 2v (IL2v) to promote the expansion and differentiation of tumor-infiltrating T cells. We hypothesize that this combination will synergistically enhance both T cell priming and expansion directly within pancreatic 4662 KPC tumors, which recapitulate the immunologically cold features of human PDAC.

Methods

Immune cell distribution and abundance following FAP-CD40/PD1-IL2v monotherapy or combination therapy were analyzed using multiplexed confocal imaging (3D immune phenotyping). FTY720 studies assessed the contribution of lymph node priming in treatment efficacy, while CD4+/CD8+ T cell depletion experiments identified the roles of these subsets in combination therapy. T cell functionality was further assessed through ex vivo restimulation assays and single-cell RNA sequencing.

Results

Combination therapy induced dense intratumoral clusters of CD4 + and CD8 + T cells, colocalized with type 1 conventional DCs, termed as T cell-DC clusters (TDCs). These TDCs were strongly associated with tumor regression, which required both CD4 + and CD8 + T cells. Furthermore, T cells from combination-treated tumors showed enhanced functionality, with increased tumor necrosis factor-alpha and interferon-gamma production compared with monotherapy groups. Single-cell RNA sequencing revealed polarization of CD4 + T cells toward a T helper cell 1 phenotype in combination-treated tumors.

Conclusion

The combination of FAP-CD40 and PD1-IL2v offers a promising strategy for treating poorly infiltrated, cold tumors. By driving T cell infiltration, promoting de novo TDC formation and orchestrating local antitumor immunity, this strategy provides a foundation for future therapies targeting immunotherapy-resistant tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dendritic CellsCD40 AntigensProgrammed Cell Death 1 ReceptorMembrane ProteinsGelatinasesInterleukin-2Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalAnimalsHumansFibroblast Activation Protein AlphaTumor MicroenvironmentMiceEndopeptidasesImmunotherapyLymphocytes, Tumor-InfiltratingCell Line, TumorFemale

Stichwörter der Autor:innen

Combination therapyImmunotherapySolid tumorTumor infiltrating lymphocyte - TILTumor microenvironment - TME

Substanzen

Fibroblast Activation Protein AlphaCD40 AntigensProgrammed Cell Death 1 ReceptorEndopeptidasesMembrane ProteinsGelatinasesInterleukin-2

Autor:innen und Institutionen

  • Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Institute of Experimental Immunology, Universität Zürich, Zürich, Switzerland.
  • Department of Immunology, Heidelberg University Medical Faculty Mannheim, Mannheim, Germany.
  • Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland leo.kunz@roche.com.

Förderung

  • F. Hoffmann-La Roche

Zitieren

APA

Nguyen, T. T., Gómez, H., Lutge, M., Yángüez, E., Hüsser, T., Nassiri, S., Trumpfheller, C., Colombetti, S., Codarri Deak, L., Umaña, P., Tugues, S., Grazina de Matos, I., & Kunz, L. (2026). FAP-CD40 and PD1-IL2v combination therapy reprograms immunologically cold tumors through de novo intratumoral T cell-dendritic cell clusters. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-014620

Vancouver

Nguyen TT, Gómez H, Lutge M, Yángüez E, Hüsser T, Nassiri S, et al. FAP-CD40 and PD1-IL2v combination therapy reprograms immunologically cold tumors through de novo intratumoral T cell-dendritic cell clusters. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-014620

BibTeX
@article{Nguyen2026,
  author = {Nguyen, Thuy Trinh and Gómez, Harold and Lutge, Mechthild and Yángüez, Emilio and Hüsser, Tamara and Nassiri, Sina and Trumpfheller, Christine and Colombetti, Sara and Codarri Deak, Laura and Umaña, Pablo and Tugues, Sònia and Grazina de Matos, Ines and Kunz, Leo},
  title = {FAP-CD40 and PD1-IL2v combination therapy reprograms immunologically cold tumors through de novo intratumoral T cell-dendritic cell clusters},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  doi = {10.1136/jitc-2025-014620}
}
Kostenlos starten →